Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.74 |
| ▸ | ERBB4 | Q15303 | 7/20 | 0.74 |
| ▸ | JAK3 | P52333 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11903417 | 1.00 | EGFR (0.74) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL17485154 | 0.92 | EGFR (0.61) | EGFRERBB2ERBB4JAK3LCK | |
| SCHEMBL11903198 | 0.91 | EGFR (0.74) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL11903105 | 0.91 | EGFR (0.74) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL11903108 | 0.91 | EGFR (0.74) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL11903094 | 0.91 | EGFR (0.74) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL11902871 | 0.85 | EGFR (0.73) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL11902865 | 0.85 | EGFR (0.73) | EGFRERBB2ERBB4JAK3KDR | |
| Th-4000E SCHEMBL11903013 | 0.82 | EGFR (0.78) | EGFRERBB2ERBB4JAK3KDR | |
| Th-4000E SCHEMBL11903016 | 0.82 | EGFR (0.78) | EGFRERBB2ERBB4JAK3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | claimed |
| US-11426409-B2 | Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210346383-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | RAIN THERAPEUTICS INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210346383-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | RAIN THERAPEUTICS INC. | 2021-11-11 | — | — | US | disclosed |
| WO-2020205627-A1 | USE OF BIOMARKER IN CANCER THERAPY | RAIN THERAPEUTICS INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2020-08-27 | — | — | US | disclosed |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2020-08-27 | — | — | US | disclosed |
| WO-2020102304-A1 | COMBINATION OF A KINASE INHIBITOR AND AN ELECTROLYTE, COMPOSITIONS AND METHODS COMPRISING THE SAME | RAIN THERAPEUTICS INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020055643-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | RAIN THERAPEUTICS INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019051155-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-04 | — | — | US | disclosed |
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-04 | — | — | US | disclosed |
| US-9101632-B2 | Kinase inhibitors, prodrug forms thereof and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-08-11 | — | — | US | disclosed |
| US-9101632-B2 | Kinase inhibitors, prodrug forms thereof and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-08-11 | — | — | US | disclosed |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | disclosed |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426409-B2 | Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers | EGFR, BRCA1, ERBB2 | EGFR 1/4885ERBB2 3/4885ERBB4 14/4885 |
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, ERBB3 | EGFR 110/4885ERBB2 1/4885ERBB4 50/4885 |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | EGFR, BRCA1, ERBB2 | EGFR 1/4885ERBB2 3/4885ERBB4 14/4885 |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, MAP3K19 | EGFR 110/4885ERBB2 1/4885ERBB4 55/4885 |
| US-20210346383-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | EGFR, VHL, MYC | EGFR 1/4885ERBB2 7/4885ERBB4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.